Unite States Soft Tissue Sarcoma Market Expected to Witness Rapid Growth until 2025
Government's focus on
R&D activities in healthcare and increasing approvals for manufacture of
generic drugs to drive United States soft tissue sarcoma market
According
to TechSci Research report, “United States Soft Tissue Sarcoma Market By Treatment (Targeted
Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease
Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User
(Hospitals, Oncology Center, Long Term Care Center), By Region, Forecast & Opportunities,
2025”, the market is expected to
witness a robust CAGR during the forecast period as the government is focusing
on investing in research and development activities to find the better
treatments for different types of cancer, including soft tissue sarcoma. The
rising awareness among people about such diseases and increasing per capita
disposable income is also making United States a favorable market for companies
manufacturing drugs for soft tissue sarcoma. Additionally, with increasing
prevalence of various types of soft tissue sarcoma in United States, the market
is poised to undergo rapid growth until 2025.
Moreover, the country is witnessing increase in
approval for manufacture of generic drugs, which is providing a major boost to
soft tissue sarcoma market. The availability of advanced healthcare system and
rise in quality patient care are some other key factors fueling the market
growth. Also, patent expiry of branded drugs and entry of new manufacturers are
some other factors anticipated to further drive United States soft tissue
sarcoma market in the coming years.
However, the market is also facing some major
restrain. U.S. FDA has reported significant shortage of some essential drugs such
as doxorubicin which is majorly employed in chemotherapy, thereby acting as a
major challenge for the manufacturers. Also, high failure rate in clinical
trials and side effects associated with cancer therapy are some other key
factors hampering the growth of United States soft tissue sarcoma market.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on "United States Soft Tissue Sarcoma
Market"
https://www.techsciresearch.com/report/united-states-soft-tissue-sarcoma-market/4856.html
The United
States soft tissue sarcoma market is segmented based on treatment, disease
type, end user and region. Based on end user, the market is segmented into
hospitals, oncology center, long term care center. Here, the oncology center
segment is undergoing fastest growth and is expected to dominate the market until
2025. The advance treatment offered by these centers is one of the key reasons
behind its high growth.
Based
on treatment, the United States soft tissue sarcoma market is segmented into
targeted therapy, chemotherapy, anti-angiogenesis drug and radiation therapy. Among
these, the high success rate of chemotherapy makes them the dominating segment
in market. It uses a combination of various anti-cancer drugs and is being
extensively carried out by oncology specialists.
Major players operating in the United
States soft tissue sarcoma market include GlaxoSmithKline LLC, Eli Lilly and
Company, Pfizer, Inc., Bristol-Myers Squibb Co, Hoffmann-La Roche Inc, Johnson
& Johnson Services, Inc., Teva Pharmaceuticals USA Inc, Celgene
Corporation, BioHorizons, Zimmer Biomet Holdings Inc and MiMedx Group Inc.
Leading manufacturers are focusing on new product launches and research &
development activities to enhance their market share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4856
Customers can also request for
10% free customization on this report.
“United
States is experiencing a significant rise in patients suffering from soft
tissue sarcoma. The Trump government is however increasing spending on
healthcare sector to provide better treatments and facilitate new drug
development in the country. Additionally, the advent of advanced therapies such
as biological and targeted therapies is providing a major boost to the market. Moreover,
the manufacturers are using latest technologies in order to provide better
treatments and drugs for soft tissue sarcoma,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based global management consulting
firm.
“United States Soft Tissue Sarcoma Market By Treatment
(Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By
Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User
(Hospitals, Oncology Center, Long Term Care Center), By Region, Forecast &
Opportunities, 2025” has
evaluated the future growth potential of United States soft tissue sarcoma market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in United States soft tissue sarcoma market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email:
[email protected]